Immunotherapy agent yields full and partial remissions in aggressive non-Hodgkin lymphomas

(Dana-Farber Cancer Institute) An immunotherapy drug able to induce lasting remissions in classical Hodgkin lymphoma may be equally effective in patients with either of two rare, aggressive forms of non-Hodgkin lymphoma, results from a small case study from Dana-Farber Cancer Institute researchers.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news